惠譽料今年中國壽險業保費增速繼續疲弱
評級機構惠譽發表報告指,保險需求疲弱加上資本市場波動令今年中國壽險公司的業務增長及盈利承壓。但穩定的不透明非標投資敞口以及堅實的償付能力緩衝水平紓解了有關挑戰。
報告指,鑑於近期因新冠肺炎疫情反彈,包括上海在內的中國部分城市採取封控措施,加上需求持續低迷,今年壽險業保費增速應會保持疲弱。惠譽預期,壽險公司對銀保渠道的依賴度將提升,並將繼續滿足客戶自疫情爆發以來日益變化的需求,而利潤率較高的代理人業務持續承壓。
惠譽指,鑑於充滿挑戰的投資環境,大多數壽險公司可能會對投資風險保持審慎,以減少其財務狀況方面的波動性。至於今年起實施的償付能力監管新規,即中國風險導向償付能力體系(償二代)二期工程亦對高風險資產提出更高的資本金要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.